TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02202928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK
Description: 8×10\^9 autologous tumor lysate pulsed DC-CIK cells for each infusion, IV (in the vein) for four cycles, each cycle received four infusions with a 1 day interval.

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Radiotherapy
Description: 45\~50 Gy in 25-28 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 45\~50 Gy in 25-28 fractions.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Chemotherapy
Description: Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
Study: NCT00006125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study: NCT00926809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin
Description: Lansoprazole, Amoxicillin 1000 mg, Clarithromycin 500 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lansoprazole (proton pump inhibitor), placebo
Description: Lansoprazole, Amoxicillin placebo, Clarythromycin placebo
Study: NCT00448422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prulifloxacin
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prulifloxacin
Description: Tablet
Study: NCT04587622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icenticaftor
Description: Single oral dose of 300 mg of icenticaftor (QBW251)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icenticaftor
Description: Single oral dose of 300 mg of icenticaftor (QBW251)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icenticaftor
Description: Single oral dose of 300 mg of icenticaftor (QBW251)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icenticaftor
Description: Single oral dose of 300 mg of icenticaftor (QBW251)
Study: NCT03571516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: SC injection of 0.05 mg/kg teduglutide will be administered QD into abdomen or into either the thigh or arm for 24 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Medical Therapy
Description: Standard medical therapy will be administered for 24 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy
Description: Standard medical therapy will be administered for 24 weeks.

Intervention type: DEVICE
Group type: OTHER
Intervention: Syringe
Description: Teduglutide will be administered using syringe (510k number: K980987).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringe
Description: Teduglutide will be administered using syringe (510k number: K980987).

Intervention type: DEVICE
Group type: OTHER
Intervention: Needle
Description: Teduglutide will be administered using needle (510k number: K021475).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle
Description: Teduglutide will be administered using needle (510k number: K021475).
Study: NCT02659332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TURBT
Description: Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of 1 ms)
Study: NCT02143843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Description: Bimatoprost Ocular Insert used continuously for 7 months, then replaced with a new Bimatoprost Ocular Insert and used continuously for another 6 months.
Study: NCT02482350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading Training
Description: Healthy subjects read moving (scrolling) text faster than static text. This type of text, also called Times Square presentation, induces a form of involuntary eye movement called optokinetic nystagmus (OKN) in the reader and, when used as part of a rehabilitation program, has been shown to improve subsequent reading performance of static text.
Study: NCT01037790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: Given orally, 125 mg QD on a 21-day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: Given orally, 125 mg QD on a 21-day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: Given orally, 125 mg QD on a 21-day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: Given orally, 125 mg QD on a 21-day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: Given orally, 125 mg QD on a 21-day
Study: NCT03299192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Yang Style Tai Chi

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Comprehensive Health Education relevant for Healthy Aging in Patients with Chronic Back Pain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Medical Care
Description: Medications, PT, Complementary and Integrative Health and other miscellaneous treatments as appropriate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Medical Care
Description: Medications, PT, Complementary and Integrative Health and other miscellaneous treatments as appropriate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Medical Care
Description: Medications, PT, Complementary and Integrative Health and other miscellaneous treatments as appropriate.
Study: NCT01482260

Intervention type: PROCEDURE
Intervention: Biopsy
Description: Biopsy

Intervention type: PROCEDURE
Intervention: Biopsy
Description: Biopsy

Intervention type: PROCEDURE
Intervention: Biopsy
Description: Biopsy
Study: NCT00850031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcuFocus Corneal Inlay
Description: Inlay implanted in cornea for improvement of near vision
Study: NCT04584710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTB101
Description: Oral RTB101 10 mg hard gelatin capsule once daily for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral matching placebo once daily for 2 weeks
Study: NCT02915614

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation
Description: 3-weeks of inpatient pulmonary Rehabilitation including exercise Training (daily endurance and strength Training)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: 3-weeks of inpatient pulmonary Rehabilitation including exercise Training (daily endurance and strength Training)
Study: NCT02281136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid (ALA)
Description: 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BLU-U
Description: 10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
Study: NCT01791361

Intervention type: OTHER
Intervention: Other
Description: No intervention other than routine medical care

Intervention type: OTHER
Intervention: Other
Description: No intervention other than routine medical care

Intervention type: OTHER
Intervention: Other
Description: No intervention other than routine medical care
Study: NCT00898976

Intervention type: OTHER
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study: NCT00378703

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study: NCT02677792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Family Intervention (BFI)
Description: Participating families will receive standard medical care through the Wellness and Weight Clinic, as well as the BFI. The BFI is based on family systems (Minuchin et al., 1975) and social-cognitive (Bandura, 1998) theories. Each dyad will participate in simultaneous, but separate, 75-minute parent and child groups over a 3 month period. The groups will start off meeting every week for 8 weeks and then bi-weekly for 1 month. Thus, dyads will attend a total of 10 group meetings over the 3 month period (12.5 hours of total treatment contact).
Study: NCT00205712

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Ketamine without dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Ketamine plus dexmedetomidine
Study: NCT03887039

Intervention type: OTHER
Intervention: clinical examination
Description: clinical examination for all the oral findings

Intervention type: OTHER
Intervention: clinical examination
Description: clinical examination for all the oral findings
Study: NCT02515539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardiAQ TMVI System (Transapical & Transfemoral DS)
Description: CardiAQ TMVI System using either the Transapical or Transfemoral Delivery System
Study: NCT02510911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg)
Description: Patients after laparoscopic colectomy will receive 3 times daily capsules with 100 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Description: Patients after laparoscopic colectomy will receive 3 times daily capsules with 200 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: corn starch (250 mg approx.)
Description: Patients after laparoscopic colectomy will receive 3 times daily capsules with 250 mg corn starch together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiopaque marker
Description: On the morning of the first, second and third day after surgery patients will take 1 capsule each day with radiopaque markers .~On day 4 after surgery an abdominal X-ray will be performed to localize the markers.~Each gelatin capsule contains 10 markers consisting of polyurethane encapsulated barium sulfate (40%).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiopaque marker
Description: On the morning of the first, second and third day after surgery patients will take 1 capsule each day with radiopaque markers .~On day 4 after surgery an abdominal X-ray will be performed to localize the markers.~Each gelatin capsule contains 10 markers consisting of polyurethane encapsulated barium sulfate (40%).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Radiopaque marker
Description: On the morning of the first, second and third day after surgery patients will take 1 capsule each day with radiopaque markers .~On day 4 after surgery an abdominal X-ray will be performed to localize the markers.~Each gelatin capsule contains 10 markers consisting of polyurethane encapsulated barium sulfate (40%).
Study: NCT03091803

Intervention type: DEVICE
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo GOCART DCE MRI

Intervention type: DEVICE
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo GOCART DCE MRI

Intervention type: DRUG
Intervention: Gadobenate Dimeglumine
Description: Given IV

Intervention type: DRUG
Intervention: Gadoterate Meglumine
Description: Given IV

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Undergo QSM and T1WI imaging

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Undergo QSM and T1WI imaging
Study: NCT00120432

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% tropicamide and 10% phenylephrine
Description: single dose vs three doses of 1%tropicamide and 10%phenylephrine
Study: NCT00568464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCR, CTX, ADM; IFO, VP-16
Description: VCD: VCR 2 mg d1, CTX 1200 mg/m2 d1, Mesna 240 mg/m2 tid d1, ADM 75mg/m2 d1, G-CSF 300 ug/d d5-11; IE: IFO 1800mg/m2 d1-5,Mesna 360 mg/m2 tid d1-5,VP-16 100 mg/m2 d1-5,G-CSF 300 ug/d d6-12; q3w. Surgery or radiation will be done to the patients with local diseases after four cycles of VCD/IE.
Study: NCT02181634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel and Gemcitabine
Description: Nab-Paclitaxel will be administered first, at a dose of 125 mg/m² IV over a period of 30 minutes; gemcitabine will be administered second, at a dose of 1000 mg/m² over a period of 30 minutes.
Study: NCT03541356

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Delivered via the I231 POD (Precision Olfactory Delivery) device
Study: NCT02206126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy Restriction
Description: The energy restriction group was instructed to follow an energy-restricted diet (-800 kcal/day).
Study: NCT03649672

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOF Watch SX
Description: Neuromuscular monitoring via the TOF Watch SX device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOF Watch SX
Description: Neuromuscular monitoring via the TOF Watch SX device
Study: NCT00282646

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraarterial stem cell therapy
Description: catheter delivery of stem cells

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: intraarterial stem cell therapy
Description: catheter delivery of stem cells

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stem cells
Description: intraarterial application of bone marrow mononuclear cells versus placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stem cells
Description: intraarterial application of bone marrow mononuclear cells versus placebo
Study: NCT03934346

Intervention type: OTHER
Group type: OTHER
Intervention: Zinc amino acid complex
Description: Zinc in the form of a Zinc Amino Acid Complex (ZnAA) is provided with a test diet, and the amount of zinc that dissociates from the ZnAA and is thus absorbed via an ionic zinc transport pathway is determined based on the Hill transport kinetics for the respective subject.
Study: NCT03699332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indium-111-DOTA-Labetuzumab-IRDye800CW injection
Description: Tracer injection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SPECT/CT scan
Description: Abdominal and thoracic SPECT/CT scan.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CRS extended with dual-modality imaging
Description: cytoreductive surgery will be performed extended with the use of dual-modality imaging.
Study: NCT02090725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-4 Diaminopyridine
Study: NCT01328184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levonorgestrel
Description: multiple doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levonorgestrel
Description: multiple doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethinylestradiol
Description: multiple doses
Study: NCT03541356

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: L-dopa 35 mg
Description: Delivered via the I231 POD (Precision Olfactory Delivery) device via one puff to one nostril

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: L-dopa 70mg
Description: Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril
Study: NCT01328184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Microgynon + BI 10773
Description: multiple doses BI 10773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol
Description: multiple doses
Study: NCT01236716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin paclitaxel plus carboplatin
Description: Patients receive carboplatin AUC=5 q3w and nab-p 135 mg/m2 weekly for 2 weeks (on days 1 and 8 of a 21-day cycle), followed by a week of rest.
Study: NCT03541356

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: L-dopa 140 mg
Description: Delivered via the I231 POD (Precision Olfactory Delivery) device with four puffs, two to each nostril

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: L-dopa 70mg/carbidopa 7mg
Description: Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril
Study: NCT02030509

Intervention type: OTHER
Intervention: Quick diagnosis program
Study: NCT04683874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printed tray
Description: 3D printed tray
Study: NCT02972086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (BPT)
Description: A specific intervention modality that has been shown to improve key functional outcomes in youth with ADHD.
Study: NCT03299439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: a stimulation of the body or auricular points

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: a stimulation of the body or auricular points
Study: NCT02353572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Transplant
Description: Undergo autologous hematopoietic stem cell transplant
Study: NCT01118949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide is supplied as 50 mg, 100 mg, 150 mg, and 200 mg tablets. Subjects will begin a Dose-Titration Phase of Lacosamide at 100 mg/day (50 mg bid, approx. 12 hours apart, once in the morning and once in the evening) for 1 week. Three (3) weekly increases will follow until the subject reaches a dosage of 200 mg/day, 300 mg/day, or 400 mg/day, as deemed clinically appropriate. The final titration will be followed by a 6-week Maintenance Phase. Subjects who complete the Maintenance Phase have the opportunity to enroll in an open-label extension study; those who do not enroll will begin a 3-week End-of-Study Phase when Lacosamide will be tapered off gradually at a recommended rate of 200 mg/day/week.
Study: NCT01102608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 3 cycles of Ifosfamide (12g/m2) associated to Mesna (6g/m2), in i.v infusion 6 days, every 3 weeks
Study: NCT03449420

Intervention type: DIAGNOSTIC_TEST
Intervention: thromboelastography
Description: TEG5000® : Kaolin and Functional Fibrinogen tests on native blood sample
Study: NCT03501017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity program
Description: The 12-week physical activity program was implemented under the guidance of nurse, in outdoors with the group, 5 days a week with warm up and cooling down for 10 minutes and normal walking tempo at a moderate pace for 30-45 minutes (3-6 km/hour).~Application of WHO Smoking Cessation Algorithm: After fagerström test was applied, the modified smoking cessation algorithm of WHO was applied to the individuals and those who decided to quit smoking were referred to smoking cessation outpatient clinics.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Practice
Description: As routine practice, a brochure provided from the Public Health Directorate on protection from CVD was delivered to the individuals in the control group.
Study: NCT01395342

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Exercise using stationary bicycle
Description: Before exercise, blood pressure and heart rate are measured in the sitting position.~Exercise is realized using stationary bicycle (horizontal bench mode) once at week, during 20 minutes under physiotherapist supervision.~The heart rate was maintained at 20% above resting heart rate and up to 140 bpm.~After exercise is performed a leg stretching and a low back stretching. The blood pressure and heart rate are measured in the sitting position.
Study: NCT04596618

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm cooling
Description: forearm cooling will be performed for active cooling assessment.